WO2004045369A3 - Nuclear receptor-based diagnostic, therapeutic, and screening methods - Google Patents
Nuclear receptor-based diagnostic, therapeutic, and screening methods Download PDFInfo
- Publication number
- WO2004045369A3 WO2004045369A3 PCT/US2003/036229 US0336229W WO2004045369A3 WO 2004045369 A3 WO2004045369 A3 WO 2004045369A3 US 0336229 W US0336229 W US 0336229W WO 2004045369 A3 WO2004045369 A3 WO 2004045369A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nuclear receptor
- polynucleotides
- methods
- polypeptides
- therapeutic
- Prior art date
Links
- 108020005497 Nuclear hormone receptor Proteins 0.000 title abstract 6
- 102000006255 nuclear receptors Human genes 0.000 title abstract 6
- 108020004017 nuclear receptors Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 238000012216 screening Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000699660 Mus musculus Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention features nuclear receptor polypeptides, polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the nuclear receptor polypeptides and polynucleotides of the invention, and for treating conditions associated with nuclear receptor dysfunction with the nuclear receptor polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate nuclear receptor activity or levels.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003295500A AU2003295500A1 (en) | 2002-11-14 | 2003-11-12 | Nuclear receptor-based diagnostic, therapeutic, and screening methods |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42630502P | 2002-11-14 | 2002-11-14 | |
| US60/426,305 | 2002-11-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004045369A2 WO2004045369A2 (en) | 2004-06-03 |
| WO2004045369A3 true WO2004045369A3 (en) | 2007-03-01 |
Family
ID=32326328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2003/036229 WO2004045369A2 (en) | 2002-11-14 | 2003-11-12 | Nuclear receptor-based diagnostic, therapeutic, and screening methods |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003295500A1 (en) |
| WO (1) | WO2004045369A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005075990A2 (en) * | 2004-02-07 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2) |
| WO2005075983A2 (en) * | 2004-02-07 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3) |
| WO2005085865A2 (en) * | 2004-03-09 | 2005-09-15 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb) |
| WO2006005460A2 (en) * | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 2, group e, member 1 (nr2e1) |
| US9484123B2 (en) | 2011-09-16 | 2016-11-01 | Prc-Desoto International, Inc. | Conductive sealant compositions |
| AU2013337353B2 (en) | 2012-11-02 | 2019-04-04 | The Johns Hopkins University | DNA methylation biomarkers of post-partum depression risk |
| US9855314B2 (en) | 2013-03-01 | 2018-01-02 | The Schepens Eye Research Insititute, Inc. | Methods for modulating development and function of photoreceptor cells |
| RU2716479C1 (en) * | 2018-09-13 | 2020-03-11 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" | Method for prediction of response to cardiac resynchronising therapy in patients with chronic heart failure |
| RU2747679C1 (en) * | 2020-07-09 | 2021-05-12 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации | Method for predicting clinical course of highly differentiated neuroendocrine pancreatic tumors |
| CN112725438B (en) * | 2021-02-05 | 2023-08-22 | 深圳市宝安区妇幼保健院 | Endometrial polyp methylation marker combination, detection kit and application |
| CN115851914A (en) * | 2022-12-12 | 2023-03-28 | 复旦大学附属眼耳鼻喉科医院 | Application of LOC107985869 in preparation of ophthalmoplegia specific auxiliary diagnostic reagent |
| CN116539902A (en) * | 2023-07-05 | 2023-08-04 | 中国医学科学院北京协和医院 | Application of differential lipid molecules as lipid markers and kit |
| CN116539901A (en) * | 2023-07-06 | 2023-08-04 | 中国医学科学院北京协和医院 | Use and kit of a differential metabolite as a diagnostic marker |
-
2003
- 2003-11-12 AU AU2003295500A patent/AU2003295500A1/en not_active Abandoned
- 2003-11-12 WO PCT/US2003/036229 patent/WO2004045369A2/en not_active Application Discontinuation
Non-Patent Citations (2)
| Title |
|---|
| FERNANDEZ-GUASTI A. ET AL.: "Sex Differences in the Distribution of Androgen Receptors in the Human Hypothalamus", THE JOURNAL OF COMPARATIVE NEUROLOGY, vol. 425, 2000, pages 422 - 435, XP003008292 * |
| HAIDER N. ET AL.: "Mutation of a Nuclear Receptor Gene, NR2E3, Causes Enhanced S Cone Syndrome, a Disorder of Retinal Cell Fate", NATURE GENETICS, vol. 24, February 2000 (2000-02-01), pages 127 - 131, XP002203635 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003295500A1 (en) | 2004-06-15 |
| AU2003295500A8 (en) | 2004-06-15 |
| WO2004045369A2 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004045369A3 (en) | Nuclear receptor-based diagnostic, therapeutic, and screening methods | |
| WO2008105797A3 (en) | Polynucleotides encoding novel pcsk9 variants | |
| ATE253111T1 (en) | NUCLEIC ACID SEQUENCES ENCODING THE CAPSAICIN RECEPTOR AND POLYPEPTIDES SIMILAR TO THE CAPSAICIN RECEPTOR AND USE THEREOF | |
| JPWO2002044362A1 (en) | Diabetes treatment screening method | |
| WO2005001061A3 (en) | Polynucleotides encoding novel adiponectin receptor variants | |
| WO2008089281A3 (en) | Methods of treating diabetes | |
| WO2003063893A3 (en) | Fgfr agonists | |
| WO2000056405A3 (en) | Human tumor necrosis factor receptor-like 2 | |
| WO2004100886A3 (en) | POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY | |
| WO2004083388A3 (en) | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 | |
| WO2004039940A3 (en) | Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof | |
| WO2008061209A3 (en) | G protein coupled receptors and uses thereof | |
| WO2002083856A3 (en) | Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof | |
| WO2006116688A3 (en) | Mif agonists and antagonists and therapeutic uses thereof | |
| WO2003083078A3 (en) | Novel human cell surface protein with immunoglobulin folds, bgs-19 | |
| WO2003027231A3 (en) | Polynucleotide encoding adapter protein, pmn29 | |
| WO2004094621A3 (en) | Polynucleotide encoding a novel trp channel family member, ltrpc3, and splice variants thereof | |
| WO2007008604A3 (en) | Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof | |
| WO2004005487A3 (en) | Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42 | |
| WO2003048316A3 (en) | Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof | |
| WO2003016497A3 (en) | Molecules for disease detection and treatment | |
| WO2004090097A3 (en) | Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v | |
| WO2002072755A3 (en) | Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy27 | |
| WO2002080888A3 (en) | Estrogen receptor-related receptor alpha (err) agonist for inducing cartilage formation | |
| WO2003079746A3 (en) | A novel human g-protein coupled receptor, hgprbmy14, related to the orphan gpcr, gpr73 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |